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Human immunodeficiency virus (HIV) transmission 
remains significant in Europe. Rates of acquired immu-
nodeficiency syndrome (AIDS) have declined, but not 
in all countries. New HIV diagnoses have increased 
among native and foreign-born men who have sex 
with men. Median CD4+ T-cell count at diagnosis has 
increased, but not in all groups, and late diagnosis 
remains common. HIV infection and AIDS can be elimi-
nated in Europe with resolute prevention measures, 
early diagnosis and access to effective treatment. 
Global goals to end acquired immunodeficiency syn-
drome (AIDS) by 2030 have been set by the Joint 
United Nations Programme on HIV/AIDS (UNAIDS) [1]. 
Despite growing evidence of effective measures to pre-
vent human immunodeficiency virus (HIV) infections 
and eliminate AIDS, such as early treatment and new 
prevention interventions, HIV transmission continues 
at considerable levels in Europe [2-5]. To better under-
stand transmission patterns and identify key popula-
tions where prevention efforts need strengthening, we 
analysed HIV and AIDS surveillance data for the years 
2005 to 2014. These data are reported annually by 
the 31 countries of the European Union and European 
Economic Area (EU/EEA) to a joint database for HIV/
AIDS coordinated by the European Centre for Disease 
Prevention and Control (ECDC) and the World Health 
Organization (WHO) Regional Office for Europe. 
HIV and AIDS diagnoses in the EU/EEA in 
2014
In 2014, 29,992 people were newly diagnosed with 
HIV in the EU/EEA, a rate of 5.9 diagnoses per 100,000 
population. The majority of cases (76.8%) were men 
(9.2 per 100,000 population vs 2.6 in women). This 
was largely driven by HIV transmission attributed to 
sex between men, which accounted for 12,677 (42%) 
of all HIV diagnoses. A total of 9,833 cases (33%) were 
attributed to heterosexual contact, 1,244 (4%) to inject-
ing drug use, and for 5,908 (20%) of new diagnoses, 
the transmission mode was not reported or unknown.
Migrant status was defined as native (born in the 
reporting country) or foreign-born (born outside the 
reporting country). We adjusted for reporting delay, 
defined as the time between HIV diagnosis and the 
report of this event, using reverse Cox proportional 
hazards models. Linear regression models were used 
to test for trends, whereby the significance level was 
set at 0.05. Analysis of migrant status showed that 
more than one third (37%) of cases were foreign-born. 
The transmission patterns and migrant status of cases 
varied considerably between EU/EEA countries (Figure 
1).
In 2014, 4,020 persons in 30 EU/EEA countries were 
diagnosed with AIDS, resulting in a rate of 0.8 per 
100,000 population. AIDS rates varied markedly from 
0.1 in Slovakia to 8.5 in Latvia. The most common route 
of HIV acquisition among persons diagnosed with AIDS 
was heterosexual contact (1,771 cases, 44%), while 
1,130 cases (28.1%) were in men who have sex with 
men (MSM) and 588 (14.6%) in people who inject drugs 
(PWID). Just over one quarter (27.8%) of those diag-
nosed with AIDS in 2014 were foreign-born.
Trends in new HIV and AIDS diagnoses
Among the 27 countries reporting on new HIV diag-
noses and transmission consistently between 2005 
and 2014, the number and proportion of cases with 
known information on transmission and migrant status 
that were attributed to MSM increased significantly in 
native men from 5,319 (20% of cases) to 6,265 (29%) 
and in foreign-born men from 1,438 (6%) to 2,783 
(10%) (p value for trend < 0.001 and 0.005, respectively) 
(Figure 2).
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The proportion of cases attributed to heterosexual con-
tact was stable among native cases, with 3,322 (17%) 
in 2005 and 3,368 (16%) in 2014, but decreased among 
foreign-born cases from 7,991 cases (31%) to 5,548 
(21%) over the same period (p < 0.001). Native cases 
attributed to injecting drug use decreased over the 
period from 1,103 (4.2%) to 766 (2.9%) and cases in 
foreign-born PWID remained stable, with the exception 
of a slight increase in both groups in 2011 and 2012 
due to localised outbreaks in Athens and Bucharest 
(not tested for trend).
The overall rate of AIDS cases reported in the EU/EEA 
has halved from 2.0 per 100,000 (9,203 cases) reported 
in 2005, but has increased by 50% or more since 2005 
in Bulgaria, the Czech Republic, Hungary, Latvia, 
Lithuania and Slovenia. The number of AIDS cases has 
declined in all transmission groups, but most notably 
in native PWID (p < 0.001) and MSM (p < 0.001) and in 
native and foreign-born persons infected heterosexu-
ally (p < 0.001 for both groups) (Figure 3).
Late diagnosis and AIDS
Twenty-two EU/EEA countries reported information 
on CD4+ T-cell count/mm3 at HIV diagnosis for 18,467 
(62%) of all cases diagnosed in 2014. Of these, 8,606 
individuals (47%) had a CD4+ T-cell count at diagnosis 
of less than 350 cells/mm3, including 5,069 (27%) with 
evidence of advanced disease (CD4+ T-cells < 200/mm3) 
(Figure 4).
When stratifying by transmission group and migrant 
status, the highest proportion of people present-
ing at a later stage of HIV infection (CD4+ T-cells < 350 
cells/mm3) was observed in foreign-born and native 
PWID (63% and 60%, respectively) and the lowest 
Figure 1
Proportion of new HIV diagnoses with known mode 
of transmission, by country, transmission route and 
migration status, EU/EEA, 2014 (n = 22,443)
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and Iceland reported one case each.
Figure 2
New HIV diagnoses, by year of diagnosis, transmission 
and migration status, adjusted for reporting delay, EU/
EEA, 2005–2014 (n = 193,761)
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proportion in foreign-born and native MSM (33% and 
39%, respectively).
The median CD4+ T-cell count/mm3 by transmission 
group over time (Figure 5) increased in both native and 
foreign-born MSM (p = 0.075 and p = 0.001, respec-
tively) and in foreign-born heterosexuals (p < 0.001), 
but not in native heterosexuals (p = 0.323). For cases 
who acquired HIV through drug injection, there was 
variation over the period, with a temporary peak in 
native PWID in 2011.
Discussion and conclusions
Our analysis indicates that HIV diagnoses continue to 
increase among native and foreign-born MSM, who 
represent the largest proportion of new HIV diagno-
ses in the EU/EEA but are diagnosed earlier than other 
groups. Although new diagnoses have declined in 
heterosexuals, influenced by a large decline in cases 
among foreign-born individuals, this remains the sec-
ond most common transmission group in the EU/
EEA. Transmission related to injecting drug use has 
declined, with the exception of the outbreak reported 
in two countries in 2011 and 2012, however late diag-
nosis remains a significant problem in PWID.
At national level, the diversity of HIV epidemic pat-
terns is apparent. Differences in the population groups 
most at risk would require diversified and targeted 
approaches to best address particular national and 
sub-national variations. For countries with large, and 
in many cases growing, HIV epidemics in MSM, there 
is a pressing need to significantly scale up more effec-
tive multi-component prevention programmes based 
on the cornerstones of accessible and effective testing 
and treatment policies. They should further consider 
introducing new approaches to prevention, such as 
pre-exposure prophylaxis [6,7].
Despite the decline over the last decade, migrants still 
constitute a considerable proportion (37%) of new 
HIV diagnoses in the EU/EEA in 2014, reaching more 
than half in some countries. There is growing evidence 
that a substantial proportion of migrants, even those 
originating from HIV-endemic areas, acquire HIV after 
arrival in the EU/EEA, indicating the need for targeted 
interventions directed at this vulnerable population 
[8-11].
In all transmission categories, people continue to be 
diagnosed with HIV at an advanced stage of illness, 
particularly PWID and heterosexually acquired cases. 
These data suggest ongoing problems with access to, 
and uptake of, HIV testing in many countries [12].
Limitations to this analysis include incomplete data 
for some variables, particularly CD4+ T-cell count at 
diagnosis, transmission mode and country of birth. 
We addressed this by limiting the analysis to countries 
with more than 50% completeness of data for transmis-
sion mode and country of birth, and by performing 
sensitivity analysis for CD4+ T-cell trends over time by 
excluding countries that did not report more than 40% 
Figure 3
New AIDS diagnoses, by transmission and migration 
status, EU/EEA, 2005–2014 (n = 55,760)
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Figure 4
Proportion of HIV diagnoses by CD4+ T-cell count/mm3 
category at diagnosis, all cases and by transmission mode 
and migration status, EU/EEA, 2014 (n = 18,467)
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CD4+ T-cell data in each transmission group for the 
entire period.
HIV infection and AIDS can be eliminated in Europe 
with more resolute prevention measures, early HIV 
diagnosis and access to effective treatment [13]. The 
elimination of AIDS and of the high associated health-
care costs and mortality is achievable in Europe, but 
this will require greater investment in evidence-based 
HIV prevention measures, tailored to the local HIV epi-
demic scenario. It will further require greater attention 
to HIV testing, using new approaches to reach those at 
risk more effectively and more often.
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